Jan Odgaard-Jensen

Statistical Specialist
Novo Nordisk A/S, Søborg, Denmark
Søborg, Hovedstaden, Denmark

Presentation(s):

• OC 59.4 - Health-related quality of life, treatment burden and patient preference in patients with haemophilia A/B without inhibitors on concizumab prophylaxis: results from the phase 3 explorer8 study

  Tuesday, June 27, 2023
  15:30 – 15:45 ET